Ensysce Biosciences Inc (LACQ)


Stock Price Forecast

June 30, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Ensysce Biosciences Inc chart...

About the Company

LACQ is a blank check company formed for the purpose of effecting a merger or other business combination with a target company. Leisure is led by Lorne Weiland Daniel Silversand completed its Initial Public Offering in December 2017.

Employees

7915

Exchange

OTC PINK CURRENT

Website

leisureacq.com

$4M

Total Revenue

8K

Employees

$87M

Market Capitalization

-85.24

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $LACQ News

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

4d ago, source: Stockhouse

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans SAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / ...

Ensysce Biosciences Inc (ENSC)

27d ago, source: Investing

SAN DIEGO, CA - Ensysce Biosciences, Inc. (NASDAQ:ENSC), a biotech firm focused on enhancing prescription drug safety, has announced agreements for the immediate exercise of... SAN DIEGO, CA ...

Ensysce Biosciences Inc Ordinary Shares

25d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

1mon ago, source: Yahoo Finance

SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)(OTC PINK:ENSCW) ("Ensysce" or "Company"), a clinical-stage company applying ...

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

26d ago, source: Nasdaq

SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve ...

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

3d ago, source: Morningstar

2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported ...

Ensysce Biosciences Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

27d ago, source: Stockhouse

SAN DIEGO, CA / ACCESSWIRE / February 21, 2024/Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve prescription ...

Ensysce Biosciences Inc.

29d ago, source: TheStreet.com

Huang's Nvidia, one of the top performing stocks over the last year, will issue what's expected to be a whopper of an earnings report on Wednesday. The standard deduction reduces the amount of ...

Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

3d ago, source:

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / E ...

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

26d ago, source: Finanznachrichten

SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative chemistry to improve ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...